Steril-gene Life Sciences Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Steril-gene Life Sciences Private Limited Pharmaceutical Export Portfolio Dataset — 8 Products, $21.2M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Steril-gene Life Sciences Private Limited — Pharmaceutical Exporter Profile (2026) | 8 Products, $21.2M Trade | TransData Nexus

Steril-gene Life Sciences Private Limited

Indian Pharmaceutical Exporter · Diabetes & Endocrine Specialist · $21.2M Total Trade · DGFT Verified

Steril-gene Life Sciences Private Limited is an Indian pharmaceutical exporter with a total trade value of $21.2M across 8 products in 6 therapeutic categories. Based on 473 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Levothyroxine ($9.4M), Prednisolone ($6.5M), Clopidogrel ($3.3M).

Steril-gene Life Sciences Private Limited — Export Portfolio & Destination Treemap

Steril-gene Life Sciences Private Limited pharmaceutical export portfolio — 8 products across 6 therapeutic categories. Source: Indian Customs (DGFT).

Who is Steril-gene Life Sciences Private Limited? — Company Overview & Market Position

Steril-Gene Life Sciences Private Limited, incorporated on February 28, 2007, is a privately held Indian pharmaceutical company specializing in the development and manufacturing of finished pharmaceutical formulations. The company is headquartered at New No.15, Old No.7, Gopalakrishnan Road, T. Nagar, Chennai, Tamil Nadu 600017, India. It operates a state-of-the-art manufacturing facility in Puducherry, India, built to US FDA standards, covering approximately 81,000 square meters and operational since 2010. The facility produces a diverse range of pharmaceutical products, including tablets, capsules, syrups, and injections. Steril-Gene Life Sciences is a joint venture between Madras Pharmaceuticals, India, and Lloyd Laboratories, Philippines, both with over 40 years of experience in the pharmaceutical industry. The company's authorized capital is ₹2,160,000,000, with a paid-up capital of ₹2,126,389,560.

What Does Steril-gene Life Sciences Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Levothyroxine$9.4M 2Prednisolone

Product Portfolio — Top 8 by Export Value

Steril-gene Life Sciences Private Limited exports 8 pharmaceutical products across 6 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Levothyroxine	Diabetes & Endocrine	$9.4M	206	12.1%	3
2	Prednisolone	Respiratory	$6.5M	131	6.8%	2
3	Clopidogrel	Cardiovascular	$3.3M	65	1.3%	7
4	Spironolactone	Diuretics	$730.6K	32	0.4%	11
5	Tamoxifen	Advanced Oncology	$416.4K	13	1.7%	7
6	Methylprednisolone	Corticosteroids	$373.5K	10	1.3%	12
7	Verapamil	Cardiovascular	$300.0K	6	0.3%	11
8	Anastrozole	Advanced Oncology	$153.3K	10	0.1%	10

Steril-gene Life Sciences Private Limited exports 8 pharmaceutical products across 6 therapeutic categories with a total export value of $21.2M. The top category is Diabetes & Endocrine (44.4% of portfolio), followed by Respiratory (31.0%), indicating a concentrated portfolio with the top 5 products accounting for 96.1% of total export value.

Steril-gene Life Sciences Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Steril-Gene Life Sciences operates a world-class manufacturing facility in Puducherry, India, covering approximately 81,000 square meters and operational since 2010. The facility is designed to meet US FDA standards and produces a wide range of pharmaceutical products, including tablets, capsules, syrups, and injections. The plant is divided into four separate manufacturing units based on the category of the drug, with a built-up area of approximately 40,000 square meters. This strategic division ensures specialized production processes and adherence to global regulatory and cGMP norms.

3Key Leadership

Steril-Gene Life Sciences Private Limited is led by a team of experienced professionals. The company's directors include Sivasamy Manohar, Sulaiman Abdulhai Mohammed, Zenaida Dizon Balajadia, Lloyd Dizon Balajadia, Dennis Dizon Balajadia, Dick Dizon Balajadia, Maximo Ponce Balajadia, Alagappan ., Krishnamurthy Balakumar, Kannappan Nagappan, Chanpreet Singh Anand, and Pabitti Manjulatha. These leaders bring a wealth of experience from various sectors within the pharmaceutical industry, contributing to the company's strategic direction and operational excellence.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Steril-gene Life Sciences Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Steril-Gene Life Sciences Private Limited has established a significant presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's manufacturing facility in Puducherry is built to US FDA standards, indicating compliance with stringent regulatory requirements. Steril-Gene Life Sciences has obtained regulatory approvals from various international authorities, including the US FDA, WHO, MHRA, and TGA, facilitating market access in these regions. The company's adherence to global regulatory standards underscores its commitment to quality and safety in its pharmaceutical products.

2Emerging Markets

Steril-Gene Life Sciences Private Limited has expanded its reach into emerging markets across Africa, Latin America, and Southeast Asia. The company's manufacturing facility in Puducherry is built to US FDA standards, indicating compliance with stringent regulatory requirements. Steril-Gene Life Sciences has obtained regulatory approvals from various international authorities, including the US FDA, WHO, MHRA, and TGA, facilitating market access in these regions. The company's adherence to global regulatory standards underscores its commitment to quality and safety in its pharmaceutical products.

3Geographic Strategy

Steril-gene Life Sciences Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Steril-Gene Life Sciences Private Limited's manufacturing facility in Puducherry, India, is built to US FDA standards, indicating compliance with stringent regulatory requirements. The company has obtained regulatory approvals from various international authorities, including the US FDA, WHO, MHRA, and TGA, facilitating market access in these regions. Steril-Gene Life Sciences has a dedicated regulatory team to facilitate product registrations in various countries, preparing dossiers in CTD, ECTD, and ACTD formats as per specific country requirements.

2WHO & EU GMP

Steril-Gene Life Sciences Private Limited has obtained regulatory approvals from various international authorities, including the WHO and EU GMP, facilitating market access in these regions. The company's manufacturing facility in Puducherry, India, is built to US FDA standards, indicating compliance with stringent regulatory requirements. Steril-Gene Life Sciences has a dedicated regulatory team to facilitate product registrations in various countries, preparing dossiers in CTD, ECTD, and ACTD formats as per specific country requirements.

3CDSCO & Indian Regulatory

Steril-gene Life Sciences Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Steril-Gene Life Sciences Private Limited operates in a competitive landscape, with several key players in the pharmaceutical manufacturing sector. The company's manufacturing facility in Puducherry, India, is built to US FDA standards, indicating compliance with stringent regulatory requirements. The company has obtained regulatory approvals from various international authorities, including the US FDA, WHO, MHRA, and TGA, facilitating market access in these regions. Steril-Gene Life Sciences has a dedicated regulatory team to facilitate product registrations in various countries, preparing dossiers in CTD, ECTD, and ACTD formats as per specific country requirements.

2Key Differentiators

3Strategic Position

Frequently Asked Questions — Steril-gene Life Sciences Private Limited

How many pharmaceutical products does Steril-gene Life Sciences Private Limited export from India?

Steril-gene Life Sciences Private Limited exports 8 pharmaceutical products across 6 therapeutic categories. The top exports are Levothyroxine ($9.4M), Prednisolone ($6.5M), Clopidogrel ($3.3M), Spironolactone ($730.6K), Tamoxifen ($416.4K). Total export value is $21.2M.

What is Steril-gene Life Sciences Private Limited's total pharmaceutical export value?

Steril-gene Life Sciences Private Limited's total pharmaceutical export value is $21.2M, based on 473 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Steril-gene Life Sciences Private Limited cover?

Steril-gene Life Sciences Private Limited exports across 6 therapeutic categories. The largest are Diabetes & Endocrine (44.4%, 1 products), Respiratory (31.0%, 1 products), Cardiovascular (16.8%, 2 products).

Get Full Steril-gene Life Sciences Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.